within Pharmacolibrary.Drugs.ATC.A;

model A06AX08
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.0,
    adminDuration  = 600,
    adminMass      = 50 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 0
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A06AX08</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Tenapanor is an inhibitor of the sodium/hydrogen exchanger 3 (NHE3) located in the intestines, approved for the treatment of adults with irritable bowel syndrome with constipation (IBS-C) and, in some regions, for hyperphosphatemia in chronic kidney disease patients on dialysis.</p><h4>Pharmacokinetics</h4><p>Healthy adults, both sexes, evaluated after oral administration; tenapanor has minimal systemic absorption, thus systemic exposure is negligible.</p><h4>References</h4><ol><li><p>King, AJ, et al., &amp; Caldwell, JS (2018). Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability. <i>Science translational medicine</i> 10(456) –. DOI:<a href=&quot;https://doi.org/10.1126/scitranslmed.aam6474&quot;>10.1126/scitranslmed.aam6474</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30158152/&quot;>https://pubmed.ncbi.nlm.nih.gov/30158152</a></p></li><li><p>Yuan, G, et al., &amp; Chen, M (2024). Pharmacokinetics, Safety, and Tolerability of Tenapanor in Healthy Chinese and Caucasian Volunteers: A Randomized, Open-Label, Single-Center, Placebo-Controlled Phase 1 Study. <i>International journal of clinical practice</i> 2024 1386980–None. DOI:<a href=&quot;https://doi.org/10.1155/2024/1386980&quot;>10.1155/2024/1386980</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38481823/&quot;>https://pubmed.ncbi.nlm.nih.gov/38481823</a></p></li><li><p>Currò, D, et al., &amp; Gasbarrini, A (2023). A pharmacokinetic evaluation of tenapanor for the treatment of irritable bowel syndrome with constipation: an update of the literature. <i>Expert opinion on drug metabolism &amp; toxicology</i> 19(12) 889–894. DOI:<a href=&quot;https://doi.org/10.1080/17425255.2023.2294937&quot;>10.1080/17425255.2023.2294937</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38108081/&quot;>https://pubmed.ncbi.nlm.nih.gov/38108081</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A06AX08;
